Principal Financial Group’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-12,187
Closed -$62.6K 2369
2024
Q2
$62.6K Sell
12,187
-5,446
-31% -$33K ﹤0.01% 2263
2024
Q1
$123K Sell
17,633
-257
-1% -$1.95K ﹤0.01% 2250
2023
Q4
$159K Sell
17,890
-151
-0.8% -$1.16K ﹤0.01% 2200
2023
Q3
$172K Buy
18,041
+12
+0.1% +$156 ﹤0.01% 2189
2023
Q2
$264K Buy
+18,029
New +$252K ﹤0.01% 2109

Other funds holding PRME

Principal Financial Group's PRME Position: Q3 2024 in Review

Principal Financial Group sold out of Prime Medicine (PRME) in Q3 2024, closing a stake of 12,187 shares — an estimated $62.6K sold.

Principal Financial Group first reported a position in PRME in Q2 2023 and held it in 5 quarters. The position peaked at $264K in Q2 2023. 116 funds tracked by Wall St. Rank hold PRME as of Q3 2024.

  • Principal Financial Group reported no remaining Prime Medicine position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 12,187 Prime Medicine shares in Q3 2024, an estimated $62.6K.
  • Principal Financial Group first reported a position in Prime Medicine in Q2 2023 and held it in 5 quarters.
  • Principal Financial Group's Prime Medicine position peaked at $264K in Q2 2023.
  • 116 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.